Jonathan Kish

Flatiron Health (United States) — United States

Economics, Econometrics and Finance · Social Sciences

22h-index2.0kcitations156works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Economic and Financial Impacts of Cancer(29), Cancer Treatment and Pharmacology(22), Health Systems, Economic Evaluations, Quality of Life(19), Myeloproliferative Neoplasms: Diagnosis and Treatment(18), Advanced Breast Cancer Therapies(18)

Publications156 total

386P Survival prediction in advanced NSCLC (aNSCLC) amid evolving standards of care (SOC): Digital twin modeling incorporating LLM-extracted clinical context
ESMO Real World Data and Digital Oncology·2025Open Access
Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices
Expert Review of Hematology·2025
Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 Rearrangement: A US Real-World Chart Review
American Journal of Clinical Pathology·2023Open Access
S621 Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients
The American Journal of Gastroenterology·2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
Clinical Lymphoma Myeloma & Leukemia·2023· 12 citedOpen Access
RWD44 Use of Real-World Data for Hard-to-Identify Patient Population: Methodology and a Case Study
Value in Health·2023Open Access
Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
Journal of Clinical Oncology·2023· 2 cited
Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
Journal of Clinical Oncology·2023
CO226 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Multiple Myeloma in the US: Real-World Evaluation of Patient Characteristics and Treatment Patterns
Value in Health·2023Open Access
EPH246 Real-World Evaluation of Health Disparities in Treatment Patterns for Systemic Lupus Erythematosus
Value in Health·2023Open Access
Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
The American Journal of Managed Care·2023· 4 cited
925 REDUCING REAL-WORLD HEALTHCARE RESOURCE UTILIZATION FOR PATIENTS WITH DIABETIC GASTROPARESIS (DGP) TREATED WITH METOCLOPRAMIDE NASAL SPRAY VERSUS ORAL METOCLOPRAMIDE
Gastroenterology·2023
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline <i>BRCA</i>-Mutated Advanced HER2-Negative Breast Cancer
The Oncologist·2023· 7 citedOpen Access
Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices
Blood·2022· 1 cited
Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A US Real-World Retrospective Cohort Study
Blood·2022· 3 cited
Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study
Journal of Blood Medicine·2022· 11 citedOpen Access
EE225 Economic and Clinical Impact of a Novel, Antiviral Therapy on COVID-19 in the US
Value in Health·2022Open Access
PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
HemaSphere·2022· 2 citedOpen Access
Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).
Journal of Clinical Oncology·2022· 2 cited
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
Journal of Clinical Oncology·2022
page 1 of 8Next →

Frequent Co-authors

Bruce A. Feinberg(18), Ajeet Gajra(10), Lora E. Fleming(8), Helena M. Solo‐Gabriele(8), Christopher D. Sinigalliano(8), Lisa R. W. Plano(8), Maribeth L. Gidley(8), Samir M. Elmir(7), Tomoyuki Shibata(7), Kelly Withum(6), Jay M. Fleisher(5), Amir M. Abdelzaher(5), Guoqing He(4), Cristina Ortega(4), Mary E. Wright(4), David Wanless(4), Marjorie E. Zettler(4), Anna C. Garza(4), Djibril Liassou(4), Andrew J. Klink(4)